Rush University Cancer Center | Strategic Alliance Partners

November 05, 2024

Thomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.

January 08, 2024

Although the severity of the shortage of chemotherapy agents, particularly with the platinum-based therapies cisplatin and carboplatin, has receded from the heights seen earlier in 2023, clinicians are still dealing with its ramifications and having to strategically manage how they employ certain chemotherapies.

December 19, 2023

Alan Tan, MD, discusses how utilizing circulating tumor DNA may provide valuable insight into when to escalate vs de-escalate treatment for patients with renal cell carcinoma.

October 30, 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

February 01, 2022

Ruta D. Rao, MD, discusses factors that inform treatment selection for patients with metastatic HER2-positive breast cancer, the effects key data that emerged in 2021 have had on sequencing, strategies to mitigate toxicities associated with trastuzumab deruxtecan, and remaining questions regarding sequencing that may be the focus of ongoing research effort.

January 13, 2021

August 20, 2020

Newer, cheaper and more personalized tests means more people tested and more lives saved.

July 11, 2019

New findings may lead to novel immunotherapies against third-deadliest cancer.

July 03, 2019

Timothy M. Kuzel, MD, FACP, discusses the use of immunotherapy as a targeted approach to treating cancer.

June 20, 2019

Ruta Rao, MD, associate professor of medical oncology, Rush University Medical Center, discusses the use of abemaciclib with or without fulvestrant for the treatment of hormone receptor–positive and HER2-negative metastatic breast cancer following prior treatment with palbociclib.

June 18, 2019

Shikha Jain, MD, hematologist/oncologist, Rush University Medical Center, discusses the disparities between male and female professionals at medical conferences, specifically the American Society of Clinical Oncology (ASCO) Annual Meeting.

June 18, 2019

Mary J. Fidler, MD, associate professor, Rush University Medical Center, discusses progression-free survival (PFS) and overall survival (OS) in patients with stage IV, nonsquamous, non–small cell lung cancer patients (NSCLC) treated with first-line pemetrexed and platinum followed by pemetrexed maintenance.

April 05, 2019

Kristin J. Richardson, MD, hematology/oncology fellow at Rush University Medical Center, discusses the use of CDK4/6 inhibitors in the treatment of patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.

April 04, 2019

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

March 28, 2019

Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.

March 26, 2019

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

March 25, 2019

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.

March 20, 2019

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

November 27, 2018

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

April 13, 2018

Ruta D. Rao, MD, elaborates on the findings of the ABCSG-16, SOFT, and TEXT clinical trials and how they have shaped adjuvant treatment for ER-positive breast cancer.